Mepolizumab effectiveness and identification of super-responders in severe asthma

S. Harvey, Erin; Langton, David; H. Katelaris, Constance; Stevens, Sean; S. Farah, Claude; Gillman, Andrew; Harrington, John; Hew, Mark; Kritikos, Vicky; Radhakrishna, Naghmeh; G. Bardin, Philip; Peters, Matthew; N. Reynolds, Paul; W. Upham, John; Baraket, Melissa; Bowler, Simon; J. Bowden, Jeffrey; Chien, Jimmy; Ping Chung, Li; Grainge, Christopher; Jenkins, Christine; Katsoulotos, Gregory; Lee, Joy; M. McDonald, Vanessa; K. Reddel, Helen; Rimmer, Janet; Wark, Peter; G. Gibson, Peter

doi:10.1183/13993003.02420-2019

Public

Mepolizumab effectiveness and identification of super-responders in severe asthma

Published in European Respiratory Journal • Mar 5, 2020

Authors:

Erin S. Harvey

David Langton

Constance H. Katelaris

Abstract

Severe asthma is a high-burden disease. Real-world data on mepolizumab in patients with severe eosinophilic asthma is needed to assess whether the data from randomised controlled trials are applicable in a broader population. The Australian Mepolizumab Registry (AMR) was established with an aim to a...

Subject

Medicine

Mepolizumab

Asthma

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!